TRACON Pharmaceuticals, Inc. (TCON)

NASDAQ: TCON · IEX Real-Time Price · USD
2.30 -0.06 (-2.54%)
Jan 18, 2022 2:41 PM EST - Market open
Market Cap44.73M
Revenue (ttm)346,000
Net Income (ttm)-25.27M
Shares Out19.45M
EPS (ttm)-1.60
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume91,020
Open2.36
Previous Close2.36
Day's Range2.28 - 2.47
52-Week Range2.18 - 11.76
Beta1.77
AnalystsBuy
Price Target11.86 (+415.7%)
Earnings DateNov 3, 2021

About TCON

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and age-related macular degeneration and fibrotic diseases in the United States. Its lead clinical stage product include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include TRC102, which is a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, Phase I clini...

IndustryBiotechnology
IPO DateJan 30, 2015
Employees18
Stock ExchangeNASDAQ
Ticker SymbolTCON
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for TCON stock is "Buy." The 12-month stock price forecast is 11.86, which is an increase of 415.65% from the latest price.

Price Target
$11.86
(415.65% upside)
Analyst Consensus: Buy

News

TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

1 week ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Sa...

Pre-specified Interim Analysis Concluded with Recommendation to Continue the ENVASARC Trial

3 weeks ago - GlobeNewsWire

TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China

First Approval of a Subcutaneously Administered Checkpoint Inhibitor

1 month ago - GlobeNewsWire

5 Stocks Insiders Are Still Buying (Even As Others Cash Out)

Insider sales are generally a sign the market is about to drop, but not everyone's selling. Here are five companies with insider buying.

Other symbols:BALYATECECOR
2 months ago - InvestorPlace

TRACON Pharmaceuticals to Present at the Jefferies London Virtual Healthcare Conference

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

2 months ago - GlobeNewsWire

TRACON Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

2 months ago - GlobeNewsWire

TRACON to Report Third Quarter 2021 Financial Results and Company Highlights on November 3, 2021

SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

2 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Appointment of Carol Lam to its Board of Directors

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeut...

3 months ago - GlobeNewsWire

TRACON Pharmaceuticals and Eucure Biopharma, a Subsidiary of Biocytogen, Announce Partnership for Development of Clin...

YH001 is a potential best-in-class CTLA-4 antibody with enhanced ADCC and CDC effector functions

3 months ago - GlobeNewsWire

TRACON Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...

4 months ago - GlobeNewsWire

TRACON Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...

4 months ago - GlobeNewsWire

TRACON Pharmaceuticals on the Fast Track for Sarcoma Injection Treatments

Sarcoma is not one of the many cancers that reaches top billing in the discussion of cancer research.  The cancer starts in tissues like bone, muscle or soft tissue and affects a relatively small, 12,00...

4 months ago - Benzinga

TRACON Pharmaceuticals to Present at the Wells Fargo Virtual Healthcare Conference

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer ...

4 months ago - GlobeNewsWire

TRACON Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

5 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Results of Second Independent Data Monitoring Committee Review of Safety Data from E...

- Trial to Continue as Planned - Trial to Continue as Planned

5 months ago - GlobeNewsWire

TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

5 months ago - GlobeNewsWire

TRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

5 months ago - GlobeNewsWire

TRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million

SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), a clinical stage biopharmaceutical company focused on the development and commercializatio...

5 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock

SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), a clinical stage biopharmaceutical company focused on the development and commercializatio...

5 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, ...

SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

5 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Programming and Grantin...

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer t...

6 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma

Application Included Clinical Trial Data from Soft Tissue Sarcoma Patients Treated with Envafolimab in Phase 1 Trials

6 months ago - GlobeNewsWire

TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at ...

SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeut...

7 months ago - GlobeNewsWire

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC...

Trial to Continue as Planned Trial to Continue as Planned

7 months ago - GlobeNewsWire

TRACON Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer th...

7 months ago - GlobeNewsWire